Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials-Reference-Cited by-同舟云学术

Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials

Published:2023-08-27 Issue:1 Volume:39 Page:
ISSN:0951-3590
Container-title:Gynecological Endocrinology
language:en
Short-container-title:Gynecological Endocrinology

Author:

Venturella Roberta¹^ORCID,Rechberger Tomasz²^ORCID,Zatik János³,Wagman Rachel B.⁴,Zhu Emily⁵,Rakov Viatcheslav G.⁶^ORCID,Petraglia Felice⁷^ORCID

Affiliation:

1. Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynecology, Magna Graecia University of Catanzaro, Catanzaro, Italy

2. Second Department of Gynecology, Medical University of Lublin, Lublin, Poland

3. Szent Anna Women’s OB/GYN and Ultrasound Outpatient Clinic, Debrecen, Hungary

4. Clinical Research, Sumitomo Pharma America, Inc., Brisbane, CA, USA

5. Development Operation, Sumitomo Pharma America, Inc., Brisbane, CA, USA

6. Research and Development, Myovant Sciences GmbH, Basel, Switzerland

7. Department of Experimental, Clinical and Biomedical Sciences, Obstetrics and Gynecology, University of Florence, Careggi University Hospital, Florence, Italy

Funder

Myovant Sciences GmbH

Pfizer

Publisher

Informa UK Limited

Subject

Obstetrics and Gynecology,Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.1080/09513590.2023.2249107

Reference37 articles.

1. Moving Toward Individualized Medicine for Uterine Leiomyomas

2. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence

3. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women

4. The Management of Uterine Leiomyomas

5. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system;Investigational New Drugs;2024-08-12

2. Current and Emerging Treatment Options for Uterine Fibroids;Drugs;2023-11-03